Affordable Access

deepdyve-link
Publisher Website

Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies.

Authors
  • Musset, Lucile
  • Miyara, Makoto
  • Benveniste, Olivier
  • Charuel, Jean-Luc
  • Shikhman, Alexander
  • Boyer, Olivier
  • Fowler, Richard
  • Mammen, Andrew
  • Phillips, Joe
  • Mahler, Michael
Type
Published Article
Journal
Journal of immunology research
Publication Date
Jan 01, 2014
Volume
2014
Pages
405956–405956
Identifiers
DOI: 10.1155/2014/405956
PMID: 24741598
Source
Medline
License
Unknown

Abstract

Diagnostic tests are needed to aid in the diagnosis of necrotizing myopathies associated with statin use. This study aimed to compare different technologies for the detection of anti-HMGCR antibodies and analyze the clinical phenotype and autoantibody profile of the patients. Twenty samples from myositis patients positive for anti-HMGCR antibodies using a research addressable laser bead assay and 20 negative controls were tested for autoantibodies to HMGCR: QUANTA Lite HMGCR ELISA and QUANTA Flash HMGCR CIA. All patients were also tested for antibodies to extractable nuclear antigens and myositis related antibodies. To verify the specificity of the ELISA, 824 controls were tested. All three assays showed qualitative agreements of 100% and levels of anti-HMGCR antibodies showed significant correlation: Spearman's rho > 0.8. The mean age of the anti-HMGCR antibody positive patients was 54.4 years, 16/20 were females, and 18/20 had necrotizing myopathy (two patients were not diagnosed). Nine out of 20 anti-HMGCR positive patients were on statin. All patients with anti-HMGCR antibodies were negative for all other autoantibodies tested. Testing various controls showed high specificity (99.3%). Anti-HMGCR antibodies are not always associated with the use of statin and appear to be the exclusive autoantibody specificity in patients with statin associated myopathies.

Report this publication

Statistics

Seen <100 times